4579.T Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 09:15):

Stats
Dzisiejszy wolumen	95 100.00
Średni wolumen	124 670
Kapitalizacja rynkowa	12.87B
EPS	¥0 ( 2024-02-14 )
Następna data zysków	( ¥0 ) 2024-05-12
Last Dividend	¥0 ( N/A )
Next Dividend	¥0 ( N/A )
P/E	-39.69
ATR14	¥0.734 (0.12%)

Wolumen Korelacja

Długi: -0.01 (neutral)

Krótki: -0.62 (weak negative)

Signal:(47.079) Neutral

RaQualia Pharma Inc. Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

RaQualia Pharma Inc. Korelacja - Waluta/Towar

-0.06
( neutral )

0.31
( neutral )

0.35
( neutral )

0.14
( neutral )

-0.14
( neutral )

-0.31
( neutral )

RaQualia Pharma Inc. Finanse

Annual	2023
Przychody:	¥1.90B
Zysk brutto:	¥1.48B (77.88 %)
EPS:	¥-14.98

FY	2023
Przychody:	¥1.90B
Zysk brutto:	¥1.48B (77.88 %)
EPS:	¥-14.98

FY	2022
Przychody:	¥2.92B
Zysk brutto:	¥2.69B (92.06 %)
EPS:	¥34.50

FY	2021
Przychody:	¥2.78B
Zysk brutto:	¥2.46B (88.45 %)
EPS:	¥7.20

Financial Reports:

No articles found.

RaQualia Pharma Inc.

RaQualia Pharma Inc. engages in the research and development of pharmaceutical compounds worldwide. Its human products portfolio includes tegoprazan for gastroesophageal reflux disease, which is in phase 1 clinical trial in the United States; and grapiprant for pain management, which is in phase II clinical trial in the United States and phase I clinical trial in China, as well as in phase I clinical trial in China and the United States to treat cancer. The company also provides veterinary products such as, grapiprant for osteoarthritis in dogs; ghrelin receptor agonist to treat cancer-related anorexia/cachexia syndrome, and constipation resulting from spinal cord injury; and ELURA, a drug for the management of weight loss in cats with chronic kidney disease. In addition, it provides TRPM8 blocker for the target indication of neuropathic pain; motilin receptor agonist to treat gastrointestinal dysmotility, including gastroparesis, functional dyspepsia, and post-operative ileus; potassium-competitive acid blocker to treat gastro-esophageal reflux disease that has completed phase 1 clinical trial; 5-HT4 partial agonist to treat gastroparesis, functional dyspepsia, and chronic constipation; 5-HT2B antagonist to treat irritable bowel syndrome with diarrhea; EP4 antagonist, a pain management drugs for dogs; serotonin 5-HT2A and dopamine D2 receptor blocker to treat schizophrenia; EP4 antagonist to treat cancer that is in phase I clinical trial, as well as in phase 1 clinical trial for the indication of pain; Cyclooxygenase-2 inhibitor, Phase I clinical trials for the indication of pain; CB2 agonist; selective sodium channel blocker; P2X7 receptor antagonist, which is in Phase I clinical trials for the target indication of neuropathic pain; and retinoic acid receptor alpha agonist. It has a collaborative agreement with Interprotein Corporation, ASKA Pharmaceutical. Co., Ltd., and Epigeneron, Inc. The company was incorporated in 2008 and is headquartered in Nagoya, Japan.